PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
87.35%
Revenue growth exceeding 1.5x VET's 0.77%. David Dodd would verify if faster growth reflects superior business model.
4.79%
Cost increase while VET reduces costs. John Neff would investigate competitive disadvantage.
167.60%
Gross profit growth exceeding 1.5x VET's 2.55%. David Dodd would verify competitive advantages.
42.84%
Margin expansion exceeding 1.5x VET's 1.76%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-6.00%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
-25.00%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-5.82%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-1.24%
Both companies reducing total costs. Martin Whitman would check industry trends.
0.71%
Interest expense growth less than half of VET's 7.45%. David Dodd would verify sustainability.
-0.25%
Both companies reducing D&A. Martin Whitman would check industry patterns.
358.30%
EBITDA growth exceeding 1.5x VET's 6.53%. David Dodd would verify competitive advantages.
154.45%
EBITDA margin growth exceeding 1.5x VET's 5.71%. David Dodd would verify competitive advantages.
626.67%
Operating income growth exceeding 1.5x VET's 13.85%. David Dodd would verify competitive advantages.
381.12%
Operating margin growth exceeding 1.5x VET's 12.98%. David Dodd would verify competitive advantages.
-27.73%
Other expenses reduction while VET shows 292.30% growth. Joel Greenblatt would examine advantage.
225.26%
Pre-tax income growth exceeding 1.5x VET's 60.44%. David Dodd would verify competitive advantages.
166.86%
Pre-tax margin growth exceeding 1.5x VET's 59.21%. David Dodd would verify competitive advantages.
-667.44%
Tax expense reduction while VET shows 16.02% growth. Joel Greenblatt would examine advantage.
269.37%
Net income growth exceeding 1.5x VET's 103.69%. David Dodd would verify competitive advantages.
190.41%
Net margin growth exceeding 1.5x VET's 102.13%. David Dodd would verify competitive advantages.
267.80%
EPS growth exceeding 1.5x VET's 98.11%. David Dodd would verify competitive advantages.
268.94%
Diluted EPS growth exceeding 1.5x VET's 103.92%. David Dodd would verify competitive advantages.
0.77%
Share count reduction exceeding 1.5x VET's 1.67%. David Dodd would verify capital allocation.
-0.01%
Diluted share reduction while VET shows 0.86% change. Joel Greenblatt would examine strategy.